Results from the SWOG S1416 clinical trial showed that adding veliparib to chemotherapy can significantly extend progression-free survival times in patients with TNBC that has a “BRCA-like” phenotype.
In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine, also referred to as T-DM1) reduced the long-term risk of death or invasive disease by 46% and improved survival compared to trastuzumab alone, according to the final results of the phase III KATHERINE clinical trial led by researchers from the University of Pittsburgh and UPMC Hillman Cancer Center.
